SLC12A5 and central nervous system cancer: In TCGA glioma cohorts, low expression of SLC12A5 was significantly associated with increased tumour grade, IDH wild‐type and 1p/19q non‐codeletion status which were known molecular biomarkers (Figure 2A, Figure S1A).